CN100350900C - Diphase capsule of compound dalbergia wood and preparation method - Google Patents
Diphase capsule of compound dalbergia wood and preparation method Download PDFInfo
- Publication number
- CN100350900C CN100350900C CNB2005100187803A CN200510018780A CN100350900C CN 100350900 C CN100350900 C CN 100350900C CN B2005100187803 A CNB2005100187803 A CN B2005100187803A CN 200510018780 A CN200510018780 A CN 200510018780A CN 100350900 C CN100350900 C CN 100350900C
- Authority
- CN
- China
- Prior art keywords
- volatile oil
- capsule
- compound
- dalbergia
- flos carthami
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a traditional Chinese medicine compound dalbergia two-phase capsule with oral administration and a preparation method thereof. The compound dalbergia two-phase capsule is prepared by that dalbergia volatile oil, safflower volatile oil and hemlock parsley volatile oil are acquired from dalbergia, safflower and hemlock parsley by a supercritical or steam distillation method; water-soluble components and ethanol-soluble components in the dalbergia, the safflower and the hemlock parsley are extracted, refined, concentrated and dried; uniform granules are acquired by one-step boiling granulation; the acquired dalbergia volatile oil, the safflower volatile oil and the hemlock parsley volatile oil are mixed and prepared into dripping pills or soft capsules by auxiliary material addition; the granules and the dripping pills or the soft capsules are put in hard capsules, and the finished product can be acquired. The medicine has the advantages that the medicine reduces the volatilization of the volatile oil, reduces chemical changes and physical changes caused by mix among the components, reduces the application of other auxiliary materials by a subpackage method of liquid components and solid components, thereby reducing the cost and the dose. The compound dalbergia two-phase capsule has better treatment effect corresponding to that of compound dalbergia soft capsules and refined coronary tablets.
Description
Technical field
The present invention relates to Chinese medicine compound Lignum Dalbergiae Odoriferae biphasic capsule of a kind of oral administration and preparation method thereof.
Background technology
At present, cardiovascular and cerebrovascular disease is commonly encountered diseases and the frequently-occurring disease that middle-aged and elderly people is easily suffered from, be one of three big diseases that threaten human health, its sickness rate is about 2/1000ths, mortality rate is up to one thousandth point three, and along with raising and the variation of diet structure and the prolongation of the average life span of people's living standard, this sick sickness rate is tangible ascendant trend.The research of strengthening angina pectoris prevention and treatment is to reduce patient's slight illness, reduces the important step of myocardial infarction incidence and mortality, also becomes one of important topic of world today's medical domain.Developed the medicine of a lot of treatment cardiovascular and cerebrovascular diseases abroad, but owing to be chemosynthesis, side effect is very big, therefore seeks a kind of determined curative effect, safe, nontoxic from traditional Chinese medicine, and the new medicine preparation of taking convenience has received the concern of domestic and international medical circle.Over past ten years, form of Chinese drug has obtained develop rapidly, nowadays traditional ball is not only arranged, looses, dosage forms such as pellet, cream, dosage forms such as capsule, injection, oral liquid, drop pill, micropill in addition.Existing is that the compound preparation of principal agent treatment brain pipe disease mostly is tablet, pill and capsule with the Lignum Dalbergiae Odoriferae, such as, CN1436549A discloses a kind of treatment vascular lesions and hemorrhage thereof, and this medicine is prepared into dropping pill formulation by Lignum Dalbergiae Odoriferae, the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Scrophulariae by certain proportioning.CN1463727A discloses a kind of soft capsule preparation that is prepared into blood fat reducing, blood pressure lowering by Lignum Dalbergiae Odoriferae, the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Scrophulariae extract and refined soybean oil by certain proportioning.CN1364526A discloses a kind of treatment blood stasis type coronary heart disease, anginal nano chest relaxing preparation, and it is to be raw material by nanometer Lignum Dalbergiae Odoriferae, nano safflower, nanometer Rhizoma Chuanxiong, the pharmaceutical preparation that is mixed with by a certain percentage.The preparation of this medicine has pill, granule, capsule, microcapsule, drop pill, oral liquid etc.
Jingzhi Guanxin tablet and treating coronary heart disease granule record in one one of Chinese Pharmacopoeia version in 2000, P624.Because the Jingzhi Guanxin tablet that pharmacopeia is recorded is the coated tablet that extract powder is pressed into, onset is slow, and dose is big, takes the 6-8 sheet at every turn, so this medicine can't excellent popularization be used.The treating coronary heart disease granule adds mixing in water for oral taking, and is more convenient, but there are the shortcoming of the loss of volatile ingredient jointly in dry link in the technical process and tablet, capsule.The pill dose is big, easily causes gastrointestinal upset after the patient takes, and absorbs slowly, and produce effects is slow, and stability of drug is poor simultaneously, bioavailability is low.
Summary of the invention
The object of the present invention is to provide a kind of diphase capsule of compound dalbergia wood and preparation method thereof.
Technical scheme of the present invention is:
A kind of diphase capsule of compound dalbergia wood, it comprises the biphasic capsule of being made by following materials of weight proportions: Lignum Dalbergiae Odoriferae 60-180 part, Rhizoma Chuanxiong 120-400 part, Flos Carthami 120-240 part, Radix Salviae Miltiorrhizae 300-450 part, Radix Paeoniae Rubra 120-240 part, this biphasic capsule comprises a hard capsule, and the water-soluble components and the pure soluble constituent of solid dosage forms is housed in the hard capsule; One or more soft capsules and/or drop pill also are housed in the hard capsule, the volatile oil composition is housed in soft capsule and/or the drop pill.
Diphase capsule of compound dalbergia wood, it comprises the biphasic capsule of being made by following materials of weight proportions: 125 parts of Lignum Dalbergiae Odoriferaes, 187.5 parts of Rhizoma Chuanxiongs, 187.5 parts on Flos Carthami, 375 parts of Radix Salviae Miltiorrhizaes, 187.5 parts of Radix Paeoniae Rubra.
Diphase capsule of compound dalbergia wood, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Rhizoma Chuanxiong, Flos Carthami water-soluble components and the pure soluble constituent of the water-soluble components and the solid dosage forms that pure soluble constituent is of solid dosage forms are housed in the hard capsule, and it is the volatile oil composition of Lignum Dalbergiae Odoriferae, Rhizoma Chuanxiong, Flos Carthami that the volatile oil composition is housed in soft capsule and/or the drop pill.
The compound dalbergia wood double phases hard capsule is equipped with the volatile oil composition of compound dalbergia wood liquid condition in soft capsule and/or the drop pill.
The compound dalbergia wood double phases hard capsule is equipped with the solidified oily composition that evaporates of compound dalbergia wood in soft capsule and/or the drop pill.
The compound dalbergia wood double phases hard capsule, the composition part by weight of soft capsule and/or drop pill is: single, 21 and three monoglyceryl ester 0～0.05mg, the Cera Flava 0～6.5mg of Flos Carthami volatile oil 2～15mg, Rhizoma Chuanxiong volatile oil 2～15mg, volatile oil of Lignum Dalbergiae Odoriferae 2～15mg, Polyethylene Glycol or vegetable oil 40～110mg, gelatin 15～50mg, glycerol 12～30mg, cellulose and its derivant 0～2mg, high-molecular weight alcohol or acid 0～0.3mg, hydrogenated fatty acid, lecithin 0～3.5mg.
The compound dalbergia wood double phases hard capsule, wherein soft capsule is ball-type or ellipse; The hard capsule model is a kind of in 000,00,0,1,2,3, No. 4.
The compound dalbergia wood double phases hard capsule, wherein drop pill weight is less than 100mg; The hard capsule model is a kind of in 000,00,0,1,2,3, No. 4.
The compound dalbergia wood double phases hard capsule, wherein excipient is selected from the group of being made up of single, 21 and three monoglyceryl esters of magnesium stearate, Pulvis Talci, cellulose and its derivant, Silicon stone and its derivant, sugar, Polyethylene Glycol, wax, vegetable oil, hydrogenated fatty acid, high-molecular weight pure and mild acid and relative mixture thereof.
The preparation method of diphase capsule of compound dalbergia wood, the preparation of (1) volatile oil composition: Lignum Dalbergiae Odoriferae medical material 125g pulverizes, 25 ℃ of extraction temperature, extracting pressure 35Mpa, extraction time 4h, extraction flow 50kg/h; Obtain the volatile oil of Lignum Dalbergiae Odoriferae composition with the CO2 supercritical extraction; Flos carthami 100g pulverizes, 35 ℃ of extraction temperature, extracting pressure 25Mpa, extraction time 4h, extraction flow 50kg/h; Obtain the Flos Carthami volatile oil composition with the CO2 supercritical extraction; Rhizoma Chuanxiong medical material 200g pulverizes, 40 ℃ of extraction temperature, extracting pressure 32Mpa, extraction time 4h, extraction flow 45kg/h; Obtain the Rhizoma Chuanxiong volatile oil composition with the CO2 supercritical extraction; (2) preparation of the water-soluble components of solid dosage forms and pure soluble constituent: red rooted salvia 375g pulverizes, and adds 6 times of amount ethanol percolations, water precipitating, and supernatant is concentrate drying routinely, obtains the fine powder intermedium; In residue, add 10 times of water gagings again, extract 2 times, each 1.5 hours, filter, merging filtrate is condensed into thick paste, uses the D-101 purification by macroporous resin, collects 30% ethanol elution, concentrates, and concentrate drying obtains the Radix Salviae Miltiorrhizae fine powder routinely; Radix Paeoniae Rubra medical material 187.5g pulverizes, and add 10 times of water gagings and extract 3 times, each 1 hour, filter, merging filtrate is condensed into thick paste, uses the D-101 purification by macroporous resin, collects 30% ethanol elution, concentrates, and concentrate drying obtains the Radix Paeoniae Rubra fine powder routinely; The Rhizoma Chuanxiong medicinal material extract residue behind the volatile oil composition pulverize, add 10 times of amount 40% ethanol extractions 1.5 hours, filter merging filtrate, be condensed into thick paste, use the D-101 purification by macroporous resin, collect 50% ethanol elution, concentrate, concentrate drying obtains the Rhizoma Chuanxiong fine powder routinely; Flos carthami has extracted the residue behind the volatile oil composition, adds 10 times of water gagings and extracts 2 times for 60 ℃, each 1.5 hours, filters, merging filtrate is condensed into thick paste, uses the AB-8 purification by macroporous resin, collects 30% ethanol elution, concentrate, concentrate drying obtains the Flos Carthami fine powder routinely; (3) with above-mentioned Radix Salviae Miltiorrhizae fine powder, Radix Paeoniae Rubra fine powder, Flos Carthami fine powder, Rhizoma Chuanxiong fine powder mix homogeneously, adopt a step boiling granulating, obtain homogeneous granules; (4) volatile oil of Lignum Dalbergiae Odoriferae, Flos Carthami volatile oil and the Rhizoma Chuanxiong volatile oil of obtaining mixed, add adjuvant, make drop pill or soft capsule; Volatile oil of Lignum Dalbergiae Odoriferae, Flos Carthami volatile oil and Rhizoma Chuanxiong volatile oil and supplementary product consumption ratio in every drop pill or the soft capsule are: volatile oil of Lignum Dalbergiae Odoriferae 10mg, Flos Carthami volatile oil 12mg, Rhizoma Chuanxiong volatile oil 8mg, Polyethylene Glycol 100mg, gelatin 50mg, glycerol 30mg, hydroxypropyl cellulose 2mg, butoben 0.05mg, Cera Flava 3.5mg, lecithin 2.5mg; (5) granule, drop pill or soft capsule are packed in No. 1 hard capsule, seal, pack, get product.
The invention has the advantages that: diphase capsule of compound dalbergia wood comprises a hard capsule, the water-soluble components and the pure soluble constituent of solid dosage forms are housed in the hard capsule, wherein: one or more soft capsules and/or drop pill also are housed in the hard capsule, the volatile oil composition is housed in soft capsule and/or the drop pill, this diphase capsule of compound dalbergia wood is the particulate reform dosage form of Jingzhi Guanxin tablet and treating coronary heart disease, can overcome traditional Jingzhi Guanxin tablet and treating coronary heart disease granule dosage form can not finely be utilized Lignum Dalbergiae Odoriferae, Flos Carthami, the shortcoming of Rhizoma Chuanxiong volatile oil composition, volatile oil of Lignum Dalbergiae Odoriferae in the present invention simultaneously is also preferred soft capsule and/or the drop pill, Flos Carthami volatile oil and Rhizoma Chuanxiong volatile oil and supplementary product consumption ratio make the having good stability of this diphase capsule of compound dalbergia wood.
If do not adopt volatile oil of Lignum Dalbergiae Odoriferae, Flos Carthami volatile oil and Rhizoma Chuanxiong volatile oil and supplementary product consumption ratio in preferred soft capsule and/or the drop pill, then the loss of Flos Carthami volatile oil and Rhizoma Chuanxiong volatile oil is very fast, but certain Flos Carthami volatile oil and the Rhizoma Chuanxiong volatile oil of the residue of this diphase capsule of compound dalbergia wood still can guarantee reasonable curative effect.
Chinese medicine compound Lignum Dalbergiae Odoriferae biphasic capsule of the present invention has blood fat reducing, blood pressure lowering and antithrombotic, anticoagulant effect, and coronary artery dilator blood vessel effectively, improves blood circulation, reduces cholesterolemia content, protection ischemia damaged myocardium.Therefore it is used for the treatment of cardiovascular and cerebrovascular diseases such as hypertension, coronary heart disease, angina pectoris, cerebral thrombosis, retinopathy and diabetic angiopathy etc. clinically.
Chinese medicine compound Lignum Dalbergiae Odoriferae biphasic capsule of the present invention has many advantages, little as consumption, toxicity is little, efficient, easy to carry etc., compare with preparations such as the tablet of existing treatment cardiovascular and cerebrovascular disease, capsule, oral liquids, drug effect is remarkable, the bioavailability height, good stability has really reached quick-acting, purpose efficiently.Control experiment shows at random, and oral diphase capsule of compound dalbergia wood curative effect of the present invention is better than existing Jingzhi Guanxin tablet and treating coronary heart disease is particulate and FUFANG JIANGXIANG RUANJIAONANG, with the FUFANG DANSHEN DIWAN therapeutic equivalence, but than more long-acting.Therefore, diphase capsule of compound dalbergia wood of the present invention will be brought into play bigger effect clinically.
The present invention is also by the refining and pharmacodynamics screening of extraction to effective site in Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Rhizoma Chuanxiong, Flos Carthami, the Lignum Dalbergiae Odoriferae three flavor medicines in the prescription, original modified form is become the preparation of making by the effective site of extracting, make it guarantee under safe, effective, the quality controllable prerequisite, bring into play rapid-action, taking dose is little, the advantage that clinical efficacy is good.Instructions of taking: oral administered compound Lignum Dalbergiae Odoriferae biphasic capsule, one time 3-4,3 times on the one.
Below be some experimental examples:
The stability of diphase capsule of compound dalbergia wood of the present invention below is described by test:
The preliminarily stabilised test:
Influence factor's test
This product is through 2500-3000lx illumination, high temperature (40 ℃, 60 ℃) and high humidity (25 ℃ of temperature, relative humidity 75% and 92.5%) etc. under the condition, detect in sampling in 0,1,3,5,10 day, the result shows: strong illumination does not all have obvious influence to the inherent quality and the outward appearance of diphase capsule of compound dalbergia wood.
Place under the hot conditions, the result shows that 40 ℃ of conditions are placed 10 days sample appearance and inherent quality has no significant change.Place that sample begins to melt after 10 days for 60 ℃, other are all stablized.Under 80 ℃ of high temperature, capsule shells is melted, and volatile oil leaks in the soft capsule, begins to occur the small amount of degradation product after 10 days.
Placed 10 days under the hot conditions, the sample surfaces moisture absorption tarnishes, and inherent quality does not have significant change.
Accelerated test:
Sample is 40 ℃ of high temperature, and under relative humidity 75% condition, simulation is gone on the market to pack and placed three months, and sampling is investigated respectively, compares in 0 day data and collection of illustrative plates, and every index is all up to specification.3, room temperature reserved sample observing: three batches of imitation listing packing samples, place under the room temperature natural conditions to keep, respectively at investigating its every index in 1,3,6 month, and with 0 month data and collection of illustrative plates relatively, every index is all up to specification.
The stable comparing result of the diphase capsule of compound dalbergia wood that table 1 different auxiliary material is made
| Embodiment | Safflower oil (mg/ grain) | Rhizoma Chuanxiong oil (mg/ grain) | Lignum Dalbergiae Odoriferae oil (mg/ grain) | The content character | ||||||||
| 0 month | Quicken June | Long-term December | 0 month | Quicken June | Long-term December | 0 month | Quicken June | Long-term December | 0 month | Quicken June | Long-term December | |
| Embodiment 18 | 2.92 | 1.02 | 0.25 | 2.85 | 1.22 | 0.35 | 2.05 | 0.92 | 0.26 | Be hard capsule, content is brown granular, drop pill or soft capsule | Be hard capsule, content is a brown granular, caking; Drop pill or soft capsule break | Be hard capsule, content is a brown granular, caking; Drop pill or soft capsule break |
| Embodiment 19 | 3.12 | 1.35 | 1.02 | 2.85 | 1.23 | 1.08 | 2.05 | 1.52 | 1.23 | Be hard capsule, content is brown granular, drop pill or soft capsule | Be hard capsule, content is a brown granular, caking; Drop pill or soft capsule break | Be hard capsule, content is a brown granular, caking; Drop pill or soft capsule break |
| Embodiment 20 | 2.92 | 1.55 | 1.03 | 2.85 | 1.35 | 1.19 | 2.05 | 1.02 | 1.06 | Be hard capsule, content is brown granular, drop pill or soft capsule | Be hard capsule, content is a brown granular, caking; Drop pill or soft capsule break | Be hard capsule, content is a brown granular, caking; Drop pill or soft capsule break |
| Embodiment 21 | 2.92 | 2.82 | 2.79 | 2.85 | 2.78 | 2.69 | 2.05 | 1.86 | 1.82 | Be hard capsule, content is brown granular, drop pill or soft capsule | Be hard capsule, content is brown granular, drop pill or soft capsule | Be hard capsule, content is brown granular, drop pill or soft capsule |
| Embodiment 22 | 6.20 | 6.05 | 6.12 | 5.35 | 5.22 | 5.28 | 4.85 | 4.76 | 4.57 | Be hard capsule, content is brown granular, drop pill or soft capsule | Be hard capsule, content is brown granular, drop pill or soft capsule | Be hard capsule, content is brown granular, drop pill or soft capsule |
| Embodiment 23 | 15 | 14.32 | 14.06 | 15 | 14.55 | 13.97 | 15 | 14.23 | 13.55 | Be hard capsule, content is brown granular, drop pill or soft capsule | Being hard capsule. content is brown granular, drop pill or soft capsule | Be hard capsule, content is brown granular, drop pill or soft capsule |
Below by pharmacodynamics test the drug action of diphase capsule of compound dalbergia wood of the present invention is described:
Below further specify diphase capsule of compound dalbergia wood of the present invention by pharmacodynamics test drug action be better than conventional capsule and other preparations:
Wherein FUFANG JIANGXIANG RUANJIAONANG is meant the soft capsule that comprises volatile oil of Lignum Dalbergiae Odoriferae, Flos Carthami volatile oil and Rhizoma Chuanxiong volatile oil composition but do not comprise the water-soluble solid composition of Lignum Dalbergiae Odoriferae, Flos Carthami, Rhizoma Chuanxiong.
Jingzhi Guanxin tablet is to provide by recording in treating coronary heart disease tablet recipe of one one the 653rd page of Chinese Pharmacopoeia version in 2005 and preparation method thereof.
FUFANG DANSHEN DIWAN is by the medicine of buying on the market.
Diphase capsule of compound dalbergia wood sees Table 2, table 3 to the influence of hyperlipidemia model rat fat and blood pressure.
Table 2 diphase capsule of compound dalbergia wood is to the influence of hyperlipidemia model rat fat (mol/ln=10 ± SD)
| Group | Dosage | Serum cholesterol (rc) | Serum glyceride (rc) | High density lipoprotein (HoL) | Low density lipoprotein, LDL (HDt) |
| The high fat of the normal control group hyperlipidemia model group+high fat+small dose group of heavy dose group | 3ml/ 3ml/ 1.68g/kg 0.48g/kg | 112.81±15.40 318.8±40.5 234.8±30.6* 256.9±40.1* | 98.91±12.59 242.2±38.2 210.2±18.8* 214.2±18.24* | 35.8±5.3 18.41±2.16 25.2±4.25* 21.0±4.25* | 34.2±6.7 106.4±20.8 67.6±15.5* 72.3±12.6* |
*p＜0.01
Result of the test shows, the every index of hyperlipidemia model group blood fat, it is ultrawhite to remove high density lipoprotein level, and other all is higher than the normal control group, two dosage groups of diphase capsule of compound dalbergia wood all can reduce the serum glyceride level significantly, can improve the content of high density lipoprotein significantly.
Table 3 diphase capsule of compound dalbergia wood is to the influence of rat blood pressure
| Group | Before the medicine (minkPa) | Behind the medicine (minkPa) | |||
| The heavy dose of group of normal saline group small dose group | 16.68±3.6 16.35±2.3 17.22.1 | 30min | 60min | 90min | 120min |
| 16.7±5.1 14.28±1.4 15.36±2.1 | 17.01±3.0 12.89± 1.2** 13.04±1.3* | 17.0±2.8 13.4±1.1* 13.78±1.4* | 17.22±3.1 14.56±3.1 14.72±3.0 | ||
*p＜0.01 **p＜0.001
Result of the test shows that behind the administration 30min, blood pressure begins to descend.60min and 90min blood pressure lowering are more obvious, and blood pressure slowly gos up during to 120min.
Below further specify diphase capsule of compound dalbergia wood of the present invention by pharmacodynamics test drug action be better than conventional capsule and other preparations:
Relatively the different preparations of compound dalbergia wood see Table 4 to the influence that folder closes mice trachea electrocardio extinction time.
The different preparations of table 4 close the influence of mice trachea electrocardio extinction time to folder
| Group | Dosage (mg/kg) | Number of animals | Electrocardio extinction time (min) (x ± SE) |
| Normal saline FUFANG DANSHEN DIWAN diphase capsule of compound dalbergia wood FUFANG JIANGXIANG RUANJIAONANG Jingzhi Guanxin tablet | 150 150 150 150 150 | 10 10 10 10 10 | 4.48±2.93 7.30±2.59* 11.36±6.39** 4.43±4.98 4.60±7.28 |
* P＜0.05, * * P＜0.01 is compared with the normal saline group.
Experimental result shows: diphase capsule of compound dalbergia wood of the present invention and FUFANG DANSHEN DIWAN have the folder of prolongation and close effect little, Mus trachea electrocardio extinction time, than FUFANG JIANGXIANG RUANJIAONANG significant difference are arranged, and have anti-myocardium piece oxygen effect.
Relatively the different preparations of compound dalbergia wood see Table 5 to the influence of rat platelet adhesion.
The different preparations of table 5 are to the influence of rat platelet adhesion
| Group | Dosage (mg/kg) | Number of animals | Platelet adhesion reaction rate (%) | |
| Before the administration | After the administration | |||
| Normal saline | 150 | 10 | 38.29±12.55 | 38.55±14.28 |
| Diphase capsule of compound dalbergia wood FUFANG DANSHEN DIWAN FUFANG JIANGXIANG RUANJIAONANG | 150 150 150 | 10 10 10 | 35.95±9.88 38.28±5.59 44.51±6.19 | 23.68±5.66* 37.65±5.44 37.20±7.51 |
* with before the administration compare p＜0.05
Experimental result shows: diphase capsule of compound dalbergia wood of the present invention has the effect of remarkable reduction platelet adhesion reaction rate, is better than other preparations.
Relatively the different preparations of compound dalbergia wood see Table 6 to the influence of rat injection of pituitrin changes in heart rate rate.
The influence of table 6 injection of pituitrin changes in heart rate rate
| Group | Dosage (mg/kg) | Changes in heart rate rate (%) | ||
| 1min | 3min | 5min | ||
| Blank group propranolol group diphase capsule of compound dalbergia wood FUFANG DANSHEN DIWAN FUFANG JIANGXIANG RUANJIAONANG | -- 150 150 150 150 | -30.60±24.45 -26.66±10.65* -25.71±15.17* -31.20±14.10 -41.31±12.49 | -51.29±31.04 -33.18±13.82 -32.16±10.94 -31.29±7.73 -38.04±6.44 | -54.59±32.59 -34.88±15.22 -32.43±10.80 -31.68±5.81 -38.29±4.76 |
* compare p＜0.05 with the blank group
Experimental result shows: through pituitrin rat screening experiment, the diphase capsule of compound dalbergia wood of the present invention anoxia drug effect that resists myocardial ischemia is better than other preparations.
The specific embodiment
Embodiment 1
The preparation method of diphase capsule of compound dalbergia wood is characterized in that: the preparation of (1) volatile oil composition: Lignum Dalbergiae Odoriferae medical material 125g pulverizes, 25 ℃ of extraction temperature, extracting pressure 35Mpa, extraction time 4h, extraction flow 50kg/h; Obtain the volatile oil of Lignum Dalbergiae Odoriferae composition with the CO2 supercritical extraction; Flos carthami 100g pulverizes, 35 ℃ of extraction temperature, extracting pressure 25Mpa, extraction time 4h, extraction flow 50kg/h; Obtain the Flos Carthami volatile oil composition with the CO2 supercritical extraction; Rhizoma Chuanxiong medical material 200g pulverizes, 40 ℃ of extraction temperature, extracting pressure 32Mpa, extraction time 4h, extraction flow 45kg/h; Obtain the Rhizoma Chuanxiong volatile oil composition with the CO2 supercritical extraction; (2) preparation of the water-soluble components of solid dosage forms and pure soluble constituent: red rooted salvia 375g pulverizes, and adds 6 times of amount ethanol percolations, water precipitating, and supernatant is concentrate drying routinely, obtains the fine powder intermedium; In residue, add 10 times of water gagings again, extract 2 times, each 1.5 hours, filter, merging filtrate is condensed into thick paste, uses the D-101 purification by macroporous resin, collects 30% ethanol elution, concentrates, and concentrate drying obtains the Radix Salviae Miltiorrhizae fine powder routinely; Radix Paeoniae Rubra medical material 187.5g pulverizes, and add 10 times of water gagings and extract 3 times, each 1 hour, filter, merging filtrate is condensed into thick paste, uses the D-101 purification by macroporous resin, collects 30% ethanol elution, concentrates, and concentrate drying obtains the Radix Paeoniae Rubra fine powder routinely; The Rhizoma Chuanxiong medicinal material extract residue behind the volatile oil composition pulverize, add 10 times of amount 40% ethanol extractions 1.5 hours, filter merging filtrate, be condensed into thick paste, use the D-101 purification by macroporous resin, collect 50% ethanol elution, concentrate, concentrate drying obtains the Rhizoma Chuanxiong fine powder routinely; Flos carthami has extracted the residue behind the volatile oil composition, adds 10 times of water gagings and extracts 2 times for 60 ℃, each 1.5 hours, filters, merging filtrate is condensed into thick paste, uses the AB-8 purification by macroporous resin, collects 30% ethanol elution, concentrate, concentrate drying obtains the Flos Carthami fine powder routinely; (3) with above-mentioned Radix Salviae Miltiorrhizae fine powder, Radix Paeoniae Rubra fine powder, Flos Carthami fine powder, Rhizoma Chuanxiong fine powder mix homogeneously, adopt a step boiling granulating, obtain homogeneous granules; (4) volatile oil of Lignum Dalbergiae Odoriferae, Flos Carthami volatile oil and the Rhizoma Chuanxiong volatile oil of obtaining mixed, add adjuvant, make drop pill or soft capsule; Volatile oil of Lignum Dalbergiae Odoriferae, Flos Carthami volatile oil and Rhizoma Chuanxiong volatile oil and supplementary product consumption ratio in every drop pill or the soft capsule are: volatile oil of Lignum Dalbergiae Odoriferae 10mg, Flos Carthami volatile oil 12mg, Rhizoma Chuanxiong volatile oil 8mg, Polyethylene Glycol 100mg, gelatin 50mg, glycerol 30mg, hydroxypropyl cellulose 2mg, butoben 0.05mg, Cera Flava 3.5mg, lecithin 2.5mg; (5) granule, drop pill or soft capsule are packed in No. 1 hard capsule, seal, pack, get product.
Embodiment 2
Raw material and consumption are with example 1.Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami extract by example 1, and the thick paste after concentrating mixes, and uses the D-101 purification by macroporous resin, collects 30% ethanol elution, concentrates, and concentrate drying obtains fine powder routinely.All the other operations are with example 1.
Embodiment 3
Raw material and consumption are with example 1.Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, flos carthami mix, and add 10 times of water gagings and extract 2 times, each 1 hour, filter, merging filtrate is condensed into thick paste, uses the D-101 purification by macroporous resin, collects 30% ethanol elution, concentrates, and concentrate drying obtains fine powder routinely.All the other operations are with example 1.
Embodiment 4
Raw material and consumption are with example 1.Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, flos carthami mix, and add 10 times of water gagings and extract 2 times, each 1 hour, filter, merging filtrate is condensed into thick paste, with Rhizoma Chuanxiong thick paste mix homogeneously, uses the D-101 purification by macroporous resin, collect 50% ethanol elution, concentrate, concentrate drying obtains fine powder routinely.All the other operations are with example 1.
Embodiment 5
Raw material and consumption are with example 1.Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami, Rhizoma Chuanxiong medical material mix, and add 10 times of water gagings and extract 2 times, each 2 hours, filter, merging filtrate is condensed into thick paste, uses the D-101 purification by macroporous resin, collects 50% ethanol elution, concentrates, and concentrate drying obtains fine powder routinely.All the other operations are with example 1.
Embodiment 6
Diphase capsule of compound dalbergia wood, it comprises a hard capsule, the compound dalbergia wood water-soluble components and the pure soluble constituent of solid dosage forms are housed in the hard capsule, wherein the prescription raw material of compound dalbergia wood is Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Rhizoma Chuanxiong, Flos Carthami, Lignum Dalbergiae Odoriferae effective part extract, one or more soft capsules and/or drop pill wherein also are housed in the hard capsule, compound dalbergia wood volatile oil composition is housed in soft capsule and/or the drop pill.
Embodiment 7
Be one group of ageratum double phases hard capsule below:
(1) diphase capsule of compound dalbergia wood is equipped with the volatile oil composition of compound dalbergia wood liquid condition in soft capsule and/or the drop pill.All the other are with embodiment 6.
(2) diphase capsule of compound dalbergia wood is equipped with the solidified oily composition that evaporates of compound dalbergia wood in soft capsule and/or the drop pill.All the other are with embodiment 6.
(3) diphase capsule of compound dalbergia wood, wherein soft capsule weight is less than 100mg; The hard capsule model is a kind of in 000,00,0,1,2,3, No. 4.All the other are with embodiment 6.
(4) diphase capsule of compound dalbergia wood, wherein soft capsule is ball-type or ellipse; The hard capsule model is a kind of in 000,00,0,1,2,3, No. 4.All the other are with embodiment 6.
(5) diphase capsule of compound dalbergia wood, wherein drop pill weight is less than 100mg; The hard capsule model is a kind of in 000,00,0,1,2,3, No. 4.All the other are with embodiment 6.
(6) diphase capsule of compound dalbergia wood, wherein excipient is selected from the group of being made up of single, 21 and three monoglyceryl esters of magnesium stearate, Pulvis Talci, cellulose and its derivant, Silicon stone and its derivant, sugar, Polyethylene Glycol, wax, vegetable oil, hydrogenated fatty acid, high-molecular weight pure and mild acid and relative mixture thereof.All the other are with embodiment 6.
Embodiment 8
The preparation method of diphase capsule of compound dalbergia wood is characterized in that: with the prescription crude drug of compound dalbergia wood through conventional water carry with alcohol extraction after water solublity and pure soluble substance, refining, make and can detect component content in the extract and reach more than 50%, be solidified into solid preparation; The prescription raw material of compound dalbergia wood is extracted the volatile oil composition through CO2 supercritical extraction and/or vapor distillation extracting method; With the fill of volatile oil composition in soft capsule and/or drop pill, in the hard capsule of again soft capsule and/or drop pill and solid preparation being packed into.
Embodiment 9
The part of double phases hard capsule is loaded specification:
Volatile oil made specification is respectively 100,80,60,50,40,20,10, the drop pill of 2mg.
Volatile oil made specification is respectively 100,80,60,50,40,20,10, the soft capsule of 2mg.
Specification is respectively 000,00,0,1,2,3, No. 4 hard capsule.
Embodiment 10
In No. 1 hard capsule, load one 100 or 80 or 60 or 50 or 40 or the drop pill of 30mg.All the other are with embodiment 1.
Embodiment 11
In No. 1 hard capsule, load one 100 or 80 or 60 or 50 or 40 or the soft capsule of 30mg.All the other are with embodiment 1.
Embodiment 12
In No. 1 hard capsule, load two 50 or 40 or the drop pill of 30mg.All the other are with embodiment 1.
Embodiment 13
In No. 1 hard capsule, load two 50 or 40 or the soft capsule of 30mg.All the other are with embodiment 1.
Embodiment 14
In No. 0 hard capsule, load the drop pill of three 20mg.All the other are with embodiment 1.
Embodiment 15
In No. 0 hard capsule, load the soft capsule of three 20mg.All the other are with embodiment 1.
Embodiment 16
In No. 0 hard capsule, load the drop pill of three 20mg, the soft capsule of two 10mg.All the other are with embodiment 1.
Embodiment 17
In No. 00 hard capsule, load the drop pill of three 20mg, the soft capsule of two 10mg.All the other are with embodiment 1.
It is preferred below to adopt embodiment to specify diphase capsule of compound dalbergia wood adjuvant of the present invention, to increase stability of formulation.
Embodiment 18
| Component | Amount (mg/ grain) |
| Safflower oil Rhizoma Chuanxiong oil Lignum Dalbergiae Odoriferae oil Polyethylene Glycol gelatin glycerol | 2.92 2.85 2.05 20 10 3.5 |
All the other are with embodiment 1.
Embodiment 19
| Component | Amount (mg/ grain) |
| Safflower oil cnidium oil dalbergia heartwood oil gelatin glycerine ethyl cellulose alpha-tocopherol ethyl-para-hydroxybenzoate beeswax | 3.12 2.85 2.05 10.35 8.53 0.25 0.06 0.01 0.3 |
All the other are with embodiment 1.
Embodiment 20
| Component | Amount (mg/ grain) |
| Safflower oil cnidium oil dalbergia heartwood oil polyethylene glycol gelatin glycerine ascorbic acid propylparaben beeswax | 2.92 2.85 2.05 20 10 3.35 0.1 0.01 0.95 |
All the other are with embodiment 1.
Embodiment 21
| Component | Amount (mg/ grain) |
| Safflower oil cnidium oil dalbergia heartwood oil polyethylene glycol gelatin glycerine ethyl cellulose alpha-tocopherol ethyl-para-hydroxybenzoate beeswax | 2.92 2.85 2.05 40 10 13.35 0.65 0.1 0.01 0.95 |
All the other are with embodiment 1.
Embodiment 22
| Component | Amount (mg/ grain) |
| Safflower oil cnidium oil dalbergia heartwood oil soya-bean oil gelatin glycerine hydroxyethylcellulose ascorbic acid butyl p-hydroxybenzoate beeswax | 6.20 5.35 4.85 60 30 12 3.5 0.5 0.03 0.45 |
All the other are with embodiment 1.
Embodiment 23
| Component | Amount (mg/ grain) |
| Safflower oil cnidium oil dalbergia heartwood oil polyethylene glycol gelatin glycerine hydroxypropyl cellulose inositol butyl p-hydroxybenzoate beeswax | 15 15 15 100 50 30 2 0.3 0.05 7.5 |
All the other are with embodiment 1.
Embodiment 24
The compound dalbergia wood double phases hard capsule, the composition part by weight of soft capsule and/or drop pill is: Flos Carthami volatile oil 2mg, Rhizoma Chuanxiong volatile oil 2mg, volatile oil of Lignum Dalbergiae Odoriferae 2mg, Polyethylene Glycol or vegetable oil 40mg, gelatin 15mg, glycerol 12mg.All the other are with embodiment 1.
Embodiment 25
The compound dalbergia wood double phases hard capsule, the composition part by weight of soft capsule and/or drop pill is: single, 21 and three monoglyceryl ester 0.05mg, the Cera Flava 6.5mg of Flos Carthami volatile oil 15mg, Rhizoma Chuanxiong volatile oil 15mg, volatile oil of Lignum Dalbergiae Odoriferae 15mg, Polyethylene Glycol or vegetable oil 110mg, gelatin 45mg, glycerol 30mg, cellulose and its derivant 2mg, high-molecular weight alcohol or sour 0.3mg, hydrogenated fatty acid, lecithin 3.5mg.All the other are with embodiment 1.
Embodiment 26
The compound dalbergia wood double phases hard capsule is characterized in that: the composition part by weight of soft capsule and/or drop pill is: single, 21 and three monoglyceryl ester 0.02mg, the Cera Flava 3.5mg of Flos Carthami volatile oil 8mg, Rhizoma Chuanxiong volatile oil 6mg, volatile oil of Lignum Dalbergiae Odoriferae 7mg, Polyethylene Glycol or vegetable oil 80mg, gelatin 35mg, glycerol 20mg, cellulose and its derivant 1mg, high-molecular weight alcohol or sour 0.1mg, hydrogenated fatty acid, lecithin 1.5mg.All the other are with embodiment 1.
Embodiment 27
Diphase capsule of compound dalbergia wood, it comprises the biphasic capsule of being made by following materials of weight proportions: 60 parts of Lignum Dalbergiae Odoriferaes, 400 parts of Rhizoma Chuanxiongs, 120 parts on Flos Carthami, 450 parts of Radix Salviae Miltiorrhizaes, 120 parts of Radix Paeoniae Rubra, all the other repeat each example among the embodiment 1-26 respectively.
Embodiment 28
Diphase capsule of compound dalbergia wood, it comprises the biphasic capsule of being made by following materials of weight proportions: 180 parts of Lignum Dalbergiae Odoriferaes, 120 parts of Rhizoma Chuanxiongs, 240 parts on Flos Carthami, 300 parts of Radix Salviae Miltiorrhizaes, 240 parts of Radix Paeoniae Rubra, all the other repeat each example among the embodiment 1-26 respectively.
Embodiment 29
Diphase capsule of compound dalbergia wood, it comprises the biphasic capsule of being made by following materials of weight proportions: 90 parts of Lignum Dalbergiae Odoriferaes, 200 parts of Rhizoma Chuanxiongs, 200 parts on Flos Carthami, 360 parts of Radix Salviae Miltiorrhizaes, 180 parts of Radix Paeoniae Rubra, all the other repeat each example among the embodiment 1-26 respectively.
Embodiment 30
Diphase capsule of compound dalbergia wood adopts the steam distillation method to obtain Flos Carthami volatile oil, and all the other repeat each example among the embodiment 1-29 respectively.
Embodiment 31
Diphase capsule of compound dalbergia wood adopts the steam distillation method to obtain Rhizoma Chuanxiong volatile oil, and all the other repeat each example among the embodiment 1-29 respectively.
Claims (1)
1, the preparation method of diphase capsule of compound dalbergia wood, the weight proportion of its raw material are Lignum Dalbergiae Odoriferae 125g, Rhizoma Chuanxiong 187.5g, Flos Carthami 187.5g, Radix Salviae Miltiorrhizae 375g, Radix Paeoniae Rubra 187.5g; It is characterized in that: the preparation of A, volatile oil composition: Lignum Dalbergiae Odoriferae medical material 125g pulverizes, 25 ℃ of extraction temperature, extracting pressure 35Mpa, extraction time 4h, extraction flow 50kg/h; Obtain the volatile oil of Lignum Dalbergiae Odoriferae composition with the CO2 supercritical extraction; Flos carthami 100g pulverizes, 35 ℃ of extraction temperature, extracting pressure 25Mpa, extraction time 4h, extraction flow 50kg/h; Obtain the Flos Carthami volatile oil composition with the CO2 supercritical extraction; Rhizoma Chuanxiong medical material 200g pulverizes, 40 ℃ of extraction temperature, extracting pressure 32Mpa, extraction time 4h, extraction flow 45kg/h; Obtain the Rhizoma Chuanxiong volatile oil composition with the CO2 supercritical extraction; The water-soluble components of B, solid dosage forms and the preparation of pure soluble constituent: red rooted salvia 375g pulverizes, and adds 6 times of amount ethanol percolations, water precipitating, and supernatant is concentrate drying routinely, obtains the fine powder intermedium; In residue, add 10 times of water gagings again, extract 2 times, each 1.5 hours, filter, merging filtrate is condensed into thick paste, uses the D-101 purification by macroporous resin, collects 30% ethanol elution, concentrates, and concentrate drying obtains the Radix Salviae Miltiorrhizae fine powder routinely; Radix Paeoniae Rubra medical material 187.5g pulverizes, and add 10 times of water gagings and extract 3 times, each 1 hour, filter, merging filtrate is condensed into thick paste, uses the D-101 purification by macroporous resin, collects 30% ethanol elution, concentrates, and concentrate drying obtains the Radix Paeoniae Rubra fine powder routinely; The Rhizoma Chuanxiong medicinal material extract residue behind the volatile oil composition pulverize, add 10 times of amount 40% ethanol extractions 1.5 hours, filter merging filtrate, be condensed into thick paste, use the D-101 purification by macroporous resin, collect 50% ethanol elution, concentrate, concentrate drying obtains the Rhizoma Chuanxiong fine powder routinely; Flos carthami has extracted the residue behind the volatile oil composition, adds 10 times of water gagings and extracts 2 times for 60 ℃, each 1.5 hours, filters, merging filtrate is condensed into thick paste, uses the AB-8 purification by macroporous resin, collects 30% ethanol elution, concentrate, concentrate drying obtains the Flos Carthami fine powder routinely; C, with above-mentioned Radix Salviae Miltiorrhizae fine powder, Radix Paeoniae Rubra fine powder, Flos Carthami fine powder, Rhizoma Chuanxiong fine powder mix homogeneously, adopt a step boiling granulating, obtain homogeneous granules; D, the volatile oil of Lignum Dalbergiae Odoriferae with obtaining, Flos Carthami volatile oil and Rhizoma Chuanxiong volatile oil mix, and add adjuvant, make drop pill or soft capsule; Volatile oil of Lignum Dalbergiae Odoriferae, Flos Carthami volatile oil and Rhizoma Chuanxiong volatile oil and supplementary product consumption ratio in every drop pill or the soft capsule are: volatile oil of Lignum Dalbergiae Odoriferae 10mg, Flos Carthami volatile oil 12mg, Rhizoma Chuanxiong volatile oil 8mg, Polyethylene Glycol 100mg, gelatin 50mg, glycerol 30mg, hydroxypropyl cellulose 2mg, butoben 0.05mg, Cera Flava 3.5mg, lecithin 2.5mg; E, granule, drop pill or soft capsule are packed in No. 1 hard capsule, seal, pack, get product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100187803A CN100350900C (en) | 2005-05-23 | 2005-05-23 | Diphase capsule of compound dalbergia wood and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100187803A CN100350900C (en) | 2005-05-23 | 2005-05-23 | Diphase capsule of compound dalbergia wood and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1695711A CN1695711A (en) | 2005-11-16 |
| CN100350900C true CN100350900C (en) | 2007-11-28 |
Family
ID=35348700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100187803A Expired - Fee Related CN100350900C (en) | 2005-05-23 | 2005-05-23 | Diphase capsule of compound dalbergia wood and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100350900C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102240321A (en) * | 2010-05-14 | 2011-11-16 | 中国人民解放军第三军医大学第一附属医院 | Medicinal composition for treating bone infarction and preparation method and application thereof |
| CN103784664B (en) * | 2014-01-27 | 2017-03-08 | 贵州师范大学 | A kind of prevent and treat biphasic capsule of chronic pelvic inflammatory disease and preparation method thereof and detection method |
| CN106963742B (en) * | 2016-11-07 | 2021-02-23 | 澳门大学 | Chinese medicine solid-liquid capsule and its preparation method |
| CN109939134A (en) * | 2019-04-01 | 2019-06-28 | 广州中医药大学 | A kind of application of Flos Carthami volatile oil |
| CN111000903A (en) * | 2020-01-07 | 2020-04-14 | 吉林修正药业新药开发有限公司 | Traditional Chinese medicine composition for treating blood stasis type coronary heart disease angina and preparation method thereof |
| CN116077554B (en) * | 2022-11-29 | 2023-12-26 | 神威药业集团有限公司 | Preparation method of Guanxinning composition |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1137235A (en) * | 1993-12-13 | 1996-12-04 | 科特克斯有限公司 | Biphasic capsule formulation |
| CN1147292C (en) * | 1997-12-17 | 2004-04-28 | 阿克斯肯制药公司 | Double capsule for the administration of active principles in multiple therepies |
| CN1526441A (en) * | 2003-01-08 | 2004-09-08 | 江西本草天工科技有限责任公司 | Agastache capsule for restoring healthy energy andits prepn and application |
| CN1526376A (en) * | 2003-01-08 | 2004-09-08 | 江西本草天工科技有限责任公司 | Two-phase hard capsule and its application |
-
2005
- 2005-05-23 CN CNB2005100187803A patent/CN100350900C/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1137235A (en) * | 1993-12-13 | 1996-12-04 | 科特克斯有限公司 | Biphasic capsule formulation |
| CN1147292C (en) * | 1997-12-17 | 2004-04-28 | 阿克斯肯制药公司 | Double capsule for the administration of active principles in multiple therepies |
| CN1526441A (en) * | 2003-01-08 | 2004-09-08 | 江西本草天工科技有限责任公司 | Agastache capsule for restoring healthy energy andits prepn and application |
| CN1526376A (en) * | 2003-01-08 | 2004-09-08 | 江西本草天工科技有限责任公司 | Two-phase hard capsule and its application |
Non-Patent Citations (1)
| Title |
|---|
| 中华人民共和国药典(一部) 药典委员会，624，化学工业出版社 2000 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1695711A (en) | 2005-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100350900C (en) | Diphase capsule of compound dalbergia wood and preparation method | |
| CN1628786A (en) | Medicine for treating hyperlipemia | |
| CN1895462A (en) | Nankang soft capsule for treating prostatitis | |
| CN100350899C (en) | Diphase capsule of red sage root for coronary heart disease and preparation method | |
| CN100350898C (en) | Diphase capsule of compound notoginseng and preparation method | |
| CN103690582B (en) | A kind of compositions and application thereof containing dendrobium polysaccharide and atractylis concrete | |
| CN1709451A (en) | Underleaf pearl formulation for treatig liver-gallbladder diseases and its preparing method | |
| CN1698820A (en) | Dripping pills with jaundice eliminating liver protecting functions and its preparation method | |
| CN1319550C (en) | Preparation of traditional Chinese medicine for treating cardio vascular disease, its preparation method and quality control method | |
| CN1278731C (en) | Compound bupleurum root medicinal preparation | |
| CN1193766C (en) | Gardenia total glycoside composite for curing hepatitis and its preparation method | |
| CN1853670A (en) | Coronary heart Danshen root micropellets and preparation thereof | |
| CN1833714A (en) | Hematopoietic pill medicinal preparation made from human placenta and pilose antler | |
| CN1872232A (en) | Composition of medication for curing cerebrovascular disease, and preparation method | |
| CN100566707C (en) | A kind of HOUTOU JIANWEI LING soft capsule for the treatment of gastropathy | |
| CN1220510C (en) | Chinese patent medicine with the functions of replenishing qi and blood and nourishing the heart to calm the mind, its preparation method and quality control method | |
| CN1199683C (en) | Medicine combination for reducing blood fat and preventing senescence and its medicines | |
| CN1682819A (en) | Sihuang intense heat purging dripping pill and its preparing method | |
| CN1695728A (en) | Oral taking preparation of Chinese traditional medicine for nourishing the kidney and the lung | |
| CN1872327A (en) | Composition of medicine for treating diarrhea | |
| CN1682821A (en) | Compound radical lobelia dripping pill and its preparing method | |
| CN1709461A (en) | Calculus bovis detoxifying dropping pill, and its preparing method | |
| CN103735591A (en) | Composition for treating digestive ulcer and applications thereof | |
| CN1733272A (en) | Pulean pharmaceutical preparation for treating urinary system diseases and process for preparing the same | |
| CN1720950A (en) | Compound drop pills of Chinese angelica and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071128 |